The massive adjusted EPS beat and raised organic sales guidance are positive, but the EBITDA guidance cut and $336M fire loss introduce uncertainty. Watch for insurance recovery announcements and Q3 margin trends. The stock may initially rally on the beat but face headwinds from the lowered EBITDA outlook.
Price Chart
Executive Summary
Medline reported Q2 2026 adjusted EPS of $0.50, beating consensus of $0.32 by 56%, and revenue of $7.69B, beating $7.51B by 2.3%. Organic sales guidance was raised to 9.0%-10.0% from 8.5%-9.5%, but Adjusted EBITDA guidance was cut to $3.3-$3.4B from $3.5-$3.6B, reflecting inflationary pressure, operational investments, and a $336M fire loss at the Tracy distribution center. The mixed guidance and one-time fire loss temper the strong headline beat.
Key Financial Metrics
Key Facts
- Q2 2026 net sales $7.685B, +11.6% YoY; Organic Sales +11.5%
- Q2 2026 GAAP net income $139M, -58.3% YoY, hit by $336M fire loss before insurance
- Q2 2026 Adjusted EBITDA $1.060B, +13.4% YoY; Adjusted Diluted EPS $0.50 vs consensus $0.32
- Full-year Organic Sales guidance raised to 9.0%-10.0% (from 8.5%-9.5%)
- Full-year Adjusted EBITDA guidance lowered to $3.3-$3.4B (from $3.5-$3.6B)
- Recognized $243M net IEEPA tariff refund benefits in Q2; $89M customer repayments reduced net sales
- First-half 2026 free cash flow $920M, +37.1% YoY; net leverage 2.9x
- Medline Brand segment Adjusted EBITDA margin improved to 30.1% from 26.8%
Financial Impact
Adjusted EPS beat of $0.18 (+56%) on $7.69B revenue; EBITDA guidance cut of ~$200M at midpoint
Risk Factors
- Tracy distribution center fire may cause prolonged operational disruption and higher costs
- Lowered Adjusted EBITDA guidance reflects Middle East inflationary pressure and retail softness
- Tariff refunds are non-recurring; core profitability trends need monitoring
- Quality remediation and operational investments could pressure margins
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0002046386-26-000049 |
| Document: mdln-20260805.htm | 0002046386-26-000049 |
| Document: 0002046386-26-000049-index-headers.html | 0002046386-26-000049 |
| Document: 0002046386-26-000049-index.html | 0002046386-26-000049 |
| Document: 0002046386-26-000049.txt | 0002046386-26-000049 |
| 8-K Data (Synthetic) | 0002046386-26-000049 |
Track record
30 reports on MDLN
5 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +17.95% at T+20 after the May 6, 2026 report. 5 of 8 went positive at some point.
Filters
- Nov 16, 2026today Press Release Bearish 5/10 Entry $36.40 Now $39.17 −7.61% settles Nov 23
- Nov 16, 2026today S-1 Neutral 4/10 Entry price pending
- Nov 13, 20263d ago SC 13G Neutral 3/10 Entry $42.00 Now $39.17 −6.74% settles Nov 23
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $42.00 Now $39.17 −6.74% settles Nov 23
- Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $40.71 to $39.17 Now $39.17 −3.78% ▼ −3.78% −2.09% vs SPY
- Nov 4, 202612d ago 8-K Neutral 5/10 No price data
- Nov 4, 202612d ago Press Release Bullish 6/10 Entry $40.35 to $42.16 Now $39.17 −2.92% ▲ +4.49% +5.40% vs SPY
- Nov 2, 202614d ago Institutional Cluster Bearish 4/10 Entry $34.09 to $40.91 Now $39.17 −14.90% ▼ −20.01% −20.59% vs SPY
- Oct 30, 202617d ago SC 13G/A Neutral 3/10 Entry $32.12 to $39.64 Now $39.17 +21.95% ▲ +23.41% +26.12% vs SPY
- Oct 21, 202626d ago 8-K Bearish 6/10 Entry $34.88 to $32.00 Now $39.17 −12.30% ▲ +8.26% +8.96% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers